Although a few drugs that target PPARγ, such as troglitazone, rosiglitazone, and pioglitazone, have been approved for patients with type 2 diabetes, severe adverse effects have led to interest in the discovery of more diverse and novel compounds that target PPARα or PPARγ. Here, PPARA is linked to type 2 diabetes mellitus.